The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

doi:10.1158/2159-8290.CD-13-0846

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

Cancer discovery - 1 Jun 2014

Friboulet Luc, Li Nanxin, Katayama Ryohei, Lee Christian C, Gainor Justin F, Crystal Adam S, Michellys Pierre-Yves, Awad Mark M, Yanagitani Noriko, Kim Sungjoon, Pferdekamper AnneMarie C, Li Jie, Kasibhatla Shailaja, Sun Frank, Sun Xiuying, Hua Su, McNamara Peter, Mahmood Sidra, Lockerman Elizabeth L, Fujita Naoya, Nishio Makoto, Harris Jennifer L, Shaw Alice T, Engelman Jeffrey A

Abstract excerpt

UNLABELLED: Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378), in the setting of crizotinib resistance. An interrogation of in vitro and in vivo models of acquired resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfones

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 24675041
DOI: 10.1158/2159-8290.CD-13-0846
PMCID: PMC4068971

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.PMID 24675041Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

Ceritinib for ALK-Rearranged Non–Small-Cell Lung CancerSemantic proximity Read ↗

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Second-generation ALK inhibitors: filling the non "MET" gap.Semantic proximity Read ↗

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.Semantic proximity Read ↗

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Semantic proximity Read ↗

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Semantic proximity Read ↗

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.